Editorial
doi: 10.3390/v14061193.
Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?
Affiliations
- PMID: 35746664
- PMCID: PMC9227515
- DOI: 10.3390/v14061193
Item in Clipboard
Editorial
Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?
Viruses.
.
Abstract
The recent review [...].
Conflict of interest statement
AV is an employee and shareholder of Replicor Inc.
Comment on
-
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.Viruses. 2022 Mar 22;14(4):657. doi: 10.3390/v14040657. Viruses. 2022. PMID: 35458387 Free PMC article. Review.
Similar articles
-
Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application.Viruses. 2017 Mar 21;9(3):56. doi: 10.3390/v9030056. Viruses. 2017. PMID: 28335554 Free PMC article. Review.
-
HBsAg, Subviral Particles, and Their Clearance in Establishing a Functional Cure of Chronic Hepatitis B Virus Infection.ACS Infect Dis. 2021 Jun 11;7(6):1351-1368. doi: 10.1021/acsinfecdis.0c00638. Epub 2020 Dec 10. ACS Infect Dis. 2021. PMID: 33302622 Review.
-
Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion.J Virol. 2009 Nov;83(21):11152-65. doi: 10.1128/JVI.00905-09. Epub 2009 Aug 12. J Virol. 2009. PMID: 19706705 Free PMC article.
-
Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.J Infect Dis. 2018 Jun 5;218(1):114-123. doi: 10.1093/infdis/jiy119. J Infect Dis. 2018. PMID: 29528436
-
The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.J Virol. 2015 Sep;89(18):9200-12. doi: 10.1128/JVI.00933-15. Epub 2015 Jun 24. J Virol. 2015. PMID: 26109732 Free PMC article.
Cited by
-
Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance.Front Immunol. 2024 Sep 12;15:1427519. doi: 10.3389/fimmu.2024.1427519. eCollection 2024. Front Immunol. 2024. PMID: 39328404 Free PMC article.
-
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873.ACS Med Chem Lett. 2024 Mar 22;15(4):546-554. doi: 10.1021/acsmedchemlett.4c00037. eCollection 2024 Apr 11. ACS Med Chem Lett. 2024. PMID: 38628802 Free PMC article.
-
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B.Curr Hepatol Rep. 2024 Jun;23(2):241-252. doi: 10.1007/s11901-024-00652-9. Epub 2024 Feb 10. Curr Hepatol Rep. 2024. PMID: 38699562 Free PMC article.
-
Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.Viruses. 2022 Sep 16;14(9):2052. doi: 10.3390/v14092052. Viruses. 2022. PMID: 36146858 Free PMC article. Review.
References
-
- Gane E., Yuen M.F., Yogaratnam J., Le K., Vuong J., Christopher W., Gohil V., Schwabe C., Agarwal K., Jucov A., et al. Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOPS) for the Treatment of Chronic Hepatitis B. J. Hepatol. 2021;75:S741.
-
- Aligos Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133. Press Release. 2022. [(accessed on 8 May 2022)]. Available online: https://investor.aligos.com/news-releases/news-release-details/aligos-ha...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
